Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology
(NASDAQ:MYGN), SALT LAKE CITY, Jan. 21, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced a study revealing that more patients completed hereditary cancer testing when they used an online screening tool and received education about genetic testing. The study was published in Obstetrics & Gynecology […]